AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)

 AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)


Shots:

  • The P-III THEMIS study involves assessing of Brilinta (ticagrelor) + aspirin vs aspirin monothx in patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior myocardial infarction or stroke
  • The P-III study resulted in meeting its 1EPs with the reduction in the composite of major adverse cardiovascular events (MACE) compared to aspirin alon
  • Brilinta (ticagrelor) is an oral P2Y12 receptor antagonist inhibits platelet activation, when administered in combination with aspirin prevents atherothrombotic events in adults with ACS

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post